Claims for Patent: 12,233,035

Summary for Patent: 12,233,035

Title:	Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent and statin
Abstract:	A method for reducing a composite endpoint risk of myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death in a subject including administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the patient has at least one history of diabetes, a past myocardial infarction, an unstable angina, a coronary bypass surgery, and a coronary angioplasty; wherein the patient is also administered a daily dose of statin therapy; and wherein the composite endpoint risk in the subject is reduced relative to a dosing regimen where the patient receives standard secondary prevention therapy of a statin.
Inventor(s):	Mark Nidorf
Assignee:	Murray and Poole Enterprises Ltd
Application Number:	US18/367,405
Patent Claims:	1. A method of treating and/or reducing the risk of a cardiovascular event in a patient, the method comprising: administering a composition comprising an effective amount of (i) colchicine, (ii) a salt of (i), or any combination of (i)-(ii) to a patient who is receiving concurrent treatment with at least one antiplatelet agent and with at least one colchicine-compatible statin, wherein the cardiovascular event is acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke, and wherein the composition is administered once per day, thereby treating and/or reducing the risk of the cardiovascular event in the patient. 2. The method of claim 1, wherein the patient has a coronary disease. 3. The method of claim 2, wherein the coronary disease is a clinically stable coronary disease. 4. The method of claim 1, wherein the antiplatelet agent is aspirin. 5. The method of claim 1, wherein colchicine is included in an amount of about 0.6 mg. 6. The method of claim 1, wherein colchicine is included in an amount of about 0.5 mg. 7. The method of claim 1, wherein the antiplatelet agent is one or more of an irreversible cyclooxygenase inhibitor, an adenosine diphosphate (ADP) receptor inhibitor, a phosphodiesterase inhibitor, a protease-activated receptor-1 (PAR-1) antagonist, a glycoprotein IIB/IIIA inhibitor, an adenosine reuptake inhibitor, a thromboxane inhibitor, and a thromboxane receptor antagonist. 8. The method of claim 7, wherein: (a) the irreversible cyclooxygenase inhibitor is aspirin and/or triflusal; (b) the ADP receptor inhibitor is clopidogrel, prasugrel, ticagrelor, ticlopidine, or a combination thereof; (c) the phosphodiesterase inhibitor is cilostazol; (d) the PAR-1 antagonist is vorapaxar; (e) the glycoprotein inhibitor is abciximab, eptifibatide, tirofiban, or a combination thereof; (f) the adenosine reuptake inhibitor is dipyridamole; and/or (g) the thromboxane inhibitor is terutroban. 9. The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier, diluent, or excipient. 10. The method of claim 1, wherein the statin is atorvastatin, fluvastatin, lovastatin, pitavastatin, rosuvastatin, simvastatin, pravastatin, a salt thereof, or any combination thereof. 11. The method of claim 1, wherein the composition is administered orally, topically, parenterally, ophthalmically, intraventricularly, intracranially, intraperitoneally, buccally, rectally, vaginally, intranasally, or by aerosol administration and/or inhalation spray. 12. The method of claim 1, wherein the composition is administered in the form of a tablet, capsule, liquid dose, gel or powder. 13. A method of treating and/or reducing the risk of a cardiovascular event in a patient, the method comprising: administering a tablet composition comprising no more than about 0.6 mg of: (i) colchicine, (ii) a salt of (i), or any combination of (i) and (ii), (iii) at least one antiplatelet agent, and (iv) at least one statin, and wherein the cardiovascular event is acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke. 14. The method of claim 13, wherein the patient has a coronary disease. 15. The method of claim 14, wherein the coronary disease is a clinically stable coronary disease. 16. The method of claim 13, wherein the anti-platelet agent is one or more of irreversible cyclooxygenase inhibitors, adenosine diphosphate (ADP) receptor inhibitors, phosphodiesterase inhibitors, glycoprotein IIB/IIIA inhibitors, adenosine reuptake inhibitors, thromboxane inhibitors, and thromboxane receptor antagonists. 17. The method of claim 13, wherein the statin is atorvastatin, fluvastatin, lovastatin, pitavastatin, rosuvastatin, simvastatin, pravastatin, a salt thereof, or any combination thereof. 18. The method of claim 13, wherein the composition is administered orally, topically, parenterally, ophthalmically, intraventricularly, intracranially, intraperitoneally, buccally, rectally, vaginally, intranasally, or by aerosol administration and/or inhalation spray.